What is 4D Lifetec?
4D Lifetec is at the forefront of developing innovative diagnostic solutions, specializing in non-invasive, immuno-oncological blood tests designed for the early detection of various cancers. Their technology aims to provide critical insights for patients during pivotal life stages, enhancing cancer diagnostics across the United States and Europe. The company's focus on early detection and monitoring positions it as a key player in the evolving landscape of medical diagnostics.
How much funding has 4D Lifetec raised?
4D Lifetec has raised a total of $27.9M across 2 funding rounds:
Series B
$1.9M
Private Equity
$26M
Series B (2022): $1.9M, investors not publicly disclosed
Private Equity (2023): $26M led by Xlife Sciences
Key Investors in 4D Lifetec
Xlife Sciences
Xlife Sciences AG is a Swiss entity focused on accelerating life science innovations from research to market. They specialize in biotechnology, medical technology, digital health, and AI, aiming to bring advanced health solutions to patients faster.
What's next for 4D Lifetec?
With a substantial enterprise-level funding injection, 4D Lifetec is poised for significant expansion and further development of its groundbreaking cancer detection technologies. The strategic investment will likely fuel advancements in clinical trials, regulatory approvals, and market penetration in both the US and European markets. This capital infusion signals strong confidence in the company's mission to revolutionize early cancer diagnostics and improve patient outcomes globally.
See full 4D Lifetec company page
